Cabergoline: Clinical Overview
Cabergoline is indicated for hyperprolactinemic disorders (idiopathic or due to pituitary adenomas), with a starting dose of 0.25 mg twice weekly, titrated by 0.25 mg increments every 4 weeks up to 1 mg twice weekly based on prolactin levels. 1
Indications
Cabergoline treats hyperprolactinemic disorders including:
- Prolactin-secreting microadenomas and macroadenomas
- Idiopathic hyperprolactinemia
- Restoration of fertility and sexual function in both men and women 1, 2
The drug normalizes prolactin in 95% of microadenoma patients and 77-92% of macroadenoma patients, with superior efficacy compared to bromocriptine due to higher dopamine D2 receptor affinity 2. In men specifically, cabergoline restores testosterone, sperm parameters, and erectile function at doses of 0.5-1 mg twice weekly 2.
Dosing Regimen
Start at 0.25 mg twice weekly (every 3-4 days). Increase by 0.25 mg twice weekly increments no more frequently than every 4 weeks, titrating to prolactin levels 1. Most patients achieve control with 0.25-3 mg weekly total, though resistant cases may require up to 11 mg weekly 2.
For high-dose therapy (≥3.5 mg weekly), prolactin normalizes faster, but tumor shrinkage rates are similar to lower doses (1-2.5 mg weekly) 3. After maintaining normal prolactin for 6 months, attempt discontinuation with periodic monitoring 1.
Absolute Contraindications
Cabergoline is contraindicated in patients with 1:
- Uncontrolled hypertension (critical pitfall: 58.3% of hypertensive patients in one study had uncontrolled BP when prescribed cabergoline 4)
- Known hypersensitivity to ergot derivatives
- Pre-existing cardiac valvular disease (any valve leaflet thickening, restriction, or stenosis on echocardiography)
- History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Monitoring Requirements
Before Initiating Treatment
- Cardiovascular evaluation
- Baseline echocardiography to exclude valvular disease 1
During Treatment
Month 1: Check prolactin to guide dose titration 2
Months 3-12:
- For macroadenomas: Repeat MRI at 3 months if prolactin rises or new symptoms develop (visual changes, headaches, galactorrhea, hormonal dysfunction)
- For all patients: Repeat MRI at 1 year 2
Long-term (especially high-dose therapy):
- Periodic echocardiography to monitor for valvular disease 1, 5
- Visual field testing for macroadenomas near optic chiasm 2
- Assess bone density if hypogonadism persists
- Monitor for impulse control disorders 5
Critical Clinical Considerations
Pregnancy: Discontinue cabergoline at pregnancy diagnosis. While congenital malformation rates (4.7%) are not elevated compared to the general population, live birth rates are lower when continued during pregnancy (RR 0.81) 6. Due to limited safety data, cabergoline should not be first-line for fertility treatment in hyperprolactinemia 7.
Tolerability advantage: Cabergoline causes fewer side effects than bromocriptine (nausea, headache, dizziness occur in 44-58% vs higher rates with bromocriptine), with only 7.7% experiencing severe adverse events requiring lifestyle modification 8, 2. Most patients intolerant to bromocriptine can tolerate cabergoline 7.
Resistance management: For bromocriptine-resistant prolactinomas, switching to cabergoline is the preferred strategy 5. Approximately 8-23% of patients may require surgical intervention for drug intolerance or resistance 2.
Duration of efficacy: The durability beyond 24 months has not been formally established, though real-world data shows successful long-term control, with some patients discontinuing after 10-20 years 1, 3.